LogicFlo AI, a Boston-based artificial intelligence platform designed specifically for the life sciences sector, has secured $2.7 million in seed funding to accelerate its global expansion across pharmaceutical, biotech, and medtech organizations. The round was led by Lightspeed with participation from healthcare and enterprise AI investors.
The startup's AI agent platform is already demonstrating transformative results in production environments across several global life sciences companies. Early deployments have shown medical writing timelines reduced from weeks to minutes, representing up to a 2000x reduction in time to first draft, while medical information response times have been cut from nearly two weeks to just two days.
Addressing Industry Automation Challenges
Founded by Udith Vaidyanathan and Arun Ramakrishnan, LogicFlo AI is targeting the fragmented tools and repetitive processes that characterize regulated scientific work. The platform provides intelligent AI agents that operate under human guidance across regulatory affairs, medical writing, quality assurance, and medical information teams.
"We are at a once-in-a-generation inflection point. For the first time, AI agents are capable enough to drive meaningful productivity gains in regulated scientific work, not just possible, but inevitable," said Udith Vaidyanathan, LogicFlo AI's co-founder and CEO. "While the rest of the world is focused on automation, instead of people, we are building automation for people. LogicFlo AI puts experts firmly at the center."
Vaidyanathan previously steered key business units from inside Abbott's CEO office before dropping out of Harvard Business School to build LogicFlo AI. His co-founder Arun Ramakrishnan brings deep technical expertise from Intuitive Surgical, where he led deep learning efforts and built high-precision AI models for the Da Vinci robotic system deployed in real-world surgeries.
Technical Approach and Deployment Strategy
"Traditional automation has failed life sciences because it's too rigid, too brittle, and too out of touch with how people actually work," explained Ramakrishnan, the company's CTO. "LogicFlo AI agents are different. They're intelligent, composable, production-ready, and they understand the nuance of scientific work."
The platform is currently deployed across medical affairs, regulatory, commercial, and quality teams at global pharmaceutical and medical device companies. Deployments typically begin with 20-30 active users and scale organically as teams experience the results.
LogicFlo's agents support functions across the entire life sciences value chain, including medical writing with literature-based content creation and full referencing, medical communications and information response generation, commercial content creation with compliant promotional materials and MLR workflow management, regulatory authoring for CTAs, INDs, and safety narratives, and quality and compliance documentation including SOPs, deviation reports, and CAPAs.
Investment and Growth Plans
The funding will support LogicFlo AI's global expansion and enable deeper deployment with global clients, including a Fortune 500 company already under contract. The company plans to accelerate product development, expand integrations with life sciences systems like Veeva and IQVIA, and grow its go-to-market and technical teams to meet rising industry demand.
"We're thrilled to back LogicFlo AI as they revolutionize how life sciences and biotech organizations operate," said Rohil Bagga, VP Investments at Lightspeed. "Their AI agent platform empowers medical affairs and commercial teams to build agentic workflows across diverse use cases, dramatically boosting productivity. Founders Udith and Arun combine deep domain expertise with exceptional technical acumen—we're excited to support them as they drive transformation in one of the world's most critical industries."
The company's approach of building "automation for people" rather than replacing human expertise positions it to address the unique compliance and precision requirements of regulated scientific work while delivering measurable productivity improvements across life sciences operations.
